Effect of iodine concentration of contrast media on contrast enhancement in multislice CT of the pancreas

Fenchel S; Fleiter T R; Aschoff A J; van Gessel R; Brambs H-J; Merkle E M
October 2004
British Journal of Radiology;Oct2004, Vol. 77 Issue 922, p821
Academic Journal
The purpose of this study was to determine the influence of two different iodine concentrations of the non-ionic contrast agent, Iomeprol, on contrast enhancement in multislice CT (MSCT) of the pancreas. To achieve this MSCT of the pancreas was performed in 50 patients (mean age 57+/-14 years) with suspected or known pancreatic tumours. The patients were randomly assigned to group A (n=25 patients) or group B (n=25 patients). There were no statistically significant differences in age, height or weight between the patients of the two groups. The contrast agent, Iomeprol, was injected with iodine concentrations of 300 mg ml(-1) in group A (130 ml, injection rate 5 ml s(-1)) and 400 mg ml(-1) in group B (98 ml, injection rate 5 ml s(-1)). Arterial and portal venous phase contrast enhancement (HU) of the vessels, organs, and pancreatic masses were measured and a qualitative image assessment was performed by two independent readers. In the arterial phase, Iomeprol 400 led to a significantly greater enhancement in the aorta, superior mesenteric artery, coeliac trunk, pancreas, pancreatic carcinomas, kidneys, spleen and wall of the small intestine than Iomeprol 300. Portal venous phase enhancement was significantly greater in the pancreas, pancreatic carcinomas, wall of the small intestine and portal vein with Iomeprol 400. The two independent readers considered Iomeprol 400 superior over Iomeprol 300 concerning technical quality, contribution of the contrast agent to the diagnostic value, and evaluability of vessels in the arterial phase. No differences were found for tumour delineation and evaluability of infiltration of organs adjacent to the pancreas between the two iodine concentrations. In conclusion the higher iodine concentration leads to a higher arterial phase contrast enhancement of large and small arteries in MSCT of the pancreas and therefore improves the evaluability of vessels in the arterial phase.


Related Articles

  • Intraductal Papillary-Mucinous Tumor of the Pancreas: Assessing the Grade of Malignancy from Natural History. Yamaguchi, Koji; Sugitani, Atsushi; Chijiiwa, Kazuo; Tanaka, Masao // American Surgeon;May2001, Vol. 67 Issue 5, p400 

    Intraductal papillary-mucinous tumor of the pancreas is a spectrum of conditions ranging from benign to malignant, and very few papers have referred to the natural history of this disease. In this communication the indicators of malignancy were examined from a viewpoint of natural history....

  • Unnecessary Tests and Procedures in Patients Presenting with Solid Tumors of the Pancreas. Cooper, Michol; Newman, Naeem; Ibrahim, Andrew; Lam, Edwin; Herman, Joseph; Singh, Vikesh; Wolfgang, Christopher; Pawlik, Timothy; Cameron, John; Makary, Martin // Journal of Gastrointestinal Surgery;Jul2013, Vol. 17 Issue 7, p1218 

    Background: A computed tomography (CT) scan is often the only study needed prior to surgery for resectable solid pancreas masses. However, many patients are evaluated with multiple studies and interventions that may be unnecessary. Methods: We conducted a retrospective review of patients who...

  • Solid pseudo-papillary tumor of pancreas: A rare case report and review of Indian literature. Murhekar, Kanchan; Ramakrishnan, A.Seshadri; Ramani, Balaji; Sunil, B. Jayanand; Majhi, Urmila // Journal of Cancer Research & Therapeutics;Jul-Sep2013, Vol. 9 Issue 3, p507 

    Solid pseudo-papillary tumor (SPT) of the pancreas is a rare pancreatic tumor, well known for its predilection for young women. As the tumor has favorable prognosis, differentiating it from other pancreatic tumors with aggressive behavior is necessary. We present a rare case of SPT and review...

  • A Challenging Diagnosis.  // Radiologic Technology;May/Jun2015, Vol. 86 Issue 5, p592 

    Photographs are presented of two axial computed tomography (CT) images of the abdomen acquired from different patients interpreted by the radiologist as pancreatic cancer.

  • A Real-World Case History: Fighting Pancreatic Cancer With ISCA's Personalized Treatment Program. Downey, Michael // Life Extension;Oct2014, p1 

    The article presents a case study of a 69-year-old male who was diagnosed with Stage IV Pancreatic Cancer. His family consulted with the International Strategic Cancer Alliance for treatment options and was provided with the protein Immune26, Taxol and Tarceva alongside chemotherapy. He was also...

  • Patients with pancreatic disease must have access to expert staff, says inquiry. Berry, Lisa // Cancer Nursing Practice;Dec2013, Vol. 12 Issue 10, p6 

    The article reports on the statement of the All-Party Parliamentary Group (APPG) regarding their concern on poor and inefficient care received by patients with pancreatic cancer.

  • Extrapancreatic Neoplasms Occur With Unusual Frequency in Patients With Intraductal Papillary Mucinous Tumors of the Pancreas. Sugiyama, Masanori; Atomi, Yutaka // American Journal of Gastroenterology;Feb1999, Vol. 94 Issue 2, p470 

    Objective: Intraductal papillary mucinous tumor (IPMT) of the pancreas has a favorable prognosis. Nonpancreatic primary neoplasms have potential prognostic significance in patients with IPMT. This study focused on the incidence and characteristics of nonpancreatic neoplasms in IPMT patients....

  • To Whipple or Not: Choices in Cancer Treatment. LAUGHTER, SAL; WELLBERY, CAROLINE // American Family Physician;10/1/2014, Vol. 90 Issue 7, p496 

    A personal narrative is presented which explores the author's experience of having a stage IV pancreatic cancer and being able to survive without having the Whipple procedure, a major abdominal surgery to remove tumorous parts of the pancreas.

  • Correction.  // Gut;Dec2014, Vol. 63 Issue 12, p1978 

    A correction to the an article related to International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer published in a previous issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics